ClinicalTrials.gg
RecruitingNCT06255678AFFE-PCIUpdated Feb 13, 2024

Angio-based Final Functional Effect of PCI

An observational study in Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome and Chronic Coronary Syndrome, sponsored by Medical University of Warsaw. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Medical University of Warsaw · Observational

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,005
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Acute Coronary Syndrome with a site in Poland — 12 open to participants now, 16 under way, 2 of them phase 3. Acute Coronary Syndrome · Poland.

Planned enrollment
5th of 13
2,005 · median 1,200
Started
2023
with 3 others
Observational
13 of 62
3 open now
Primary completion
2027-01
later than 8 of 15 live
Registered
54th of 62
by date
Lead sponsor
3 of 62
Medical University of Warsaw

Among the 62 studies in Acute Coronary Syndrome with a site in Poland, this one is the 5th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2023, is one of 13 observational ones, reaches primary completion later than 8 of the 15 other live ones, and was the 54th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

12 of the 62 studies in Acute Coronary Syndrome with a site in Poland are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Acute Coronary Syndrome with a site in Poland, or all of them as a file.
02

Study summary

Fractional flow reserve (FFR) has revolutionized the diagnosis and treatment of coronary artery disease (CAD), and more recently, post percutaneous coronary intervention (post-PCI) FFR has emerged as an independent predictor of cardiovascular events, enabling the identification of cases requiring additional optimization of the implanted stent. Modern technologies allow less invasive alternatives to traditional FFR measurement - angiography-based vessel fractional flow reserve (vFFR) and derivative ΔvFFR, which is calculated by a difference between the post-PCI vFFR and pre-PCI vFFR. In large clinical studies, the good accuracy between vFFR and FFR - measured before and after PCI - has been confirmed. However, insufficient data is available about the value of post-vFFR and ΔvFFR as prognostic values and indicators of patient health.

This is a prospective multicenter register study analyzing the association between the value of ΔvFFR, vFFR after PCI and adverse clinical outcomes, residual angina and quality of life using the validated Seattle Angina Questionnaire (SAQ) and EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L). Patients undergoing PCI for chronic coronary syndromes (CCS), non-ST-segment elevation acute coronary syndromes (NST-ACS) or ST-Segment Elevation Myocardial Infarction (STEMI) will be enrolled in this study.

Read the detailed description

The primary goal of this prospective multicenter register study is to evaluate the association between the value of vFFR after PCI and adverse clinical outcomes, residual angina and quality of life using the validated Seattle Angina Questionnaire (SAQ) and EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L) at 6 and 24 months following PCI. The primary composite endpoint is defined as a major adverse cardiovascular event (MACE) including all-cause death, target-vessel myocardial infarction (TVMI), and target vessel revascularization (TVR)] at 6, 12 and 24-month follow-ups. Patients undergoing PCI for chronic coronary syndromes (CCS), non-ST-segment elevation acute coronary syndromes (NST-ACS) or or ST-Segment Elevation Myocardial Infarction (STEMI) will be enrolled in this study. The analyses of the primary endpoint will be stratified according to the following subgroups:

  • Diabetes/non-diabetes
  • Glomerular filtration rate (GFR)≥60/GFR\<60 [ml/min./1,73m2]
  • Focal/diffuse atherosclerosis
  • Multivessel/single-vessel disease
  • CCS/NST-ACS/STEMI
  • CCS/ACS

The patients' coronary angiograms will be analyzed using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands) enrolled at the Invasive Cardiology Unit of the 1st Department of Cardiology, Medical University of Warsaw (Poland) and other centers in Poland.

03

Conditions studied

  • Acute Coronary Syndrome
  • Non ST Segment Elevation Acute Coronary Syndrome
  • Chronic Coronary Syndrome

Keywords

  • vFFR
  • ACS
  • NST-ACS
  • Angiography-based FFR
  • Quality of life
  • Residual angina
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with percutaneous coronary intervention (PCI) for chronic coronary syndromes (CCS) or acute coronary syndromes (ACS)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Percutaneous coronary intervention (PCI) for chronic coronary syndromes (CCS) or acute coronary syndromes (ACS)
  • Adequate quality of angiogram enabling vFFR analysis (available two angiographic views with ≥30° differences in rotation/angulation, the possibility of vessel contour selection, proper quality of the images, vessels without severe overlapping, tortuosity, foreshortening and poor vessel opacification)
  • Age >18 years
  • The patient's written has been obtained before the procedure

Exclusion criteria

Exclusion Criteria:

  • Cardiogenic shock, pulmonary oedema
  • Severe hemodynamical instability
  • Prior coronary artery bypass grafting (CABG)
  • Active bleeding
  • Acute and chronic inflammatory conditions
  • Acute mechanical complications of myocardial infarction
  • Congenital heart disease
  • Heart transplantation
  • Non-cardiac comorbidities with a of less than 1 year
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,005 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Patients undergoing PCI

    Assessment of ΔvFFR and vFFR after PCI and adverse clinical outcomes, residual angina and quality of life using the validated Seattle Angina Questionnaire (SAQ) and EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L) in patients with CCS or ACS.

    Diagnostic Test: Angiography-based vessel fractional flow reserve (vFFR) calculation

Interventions

  • Diagnostic testAngiography-based vessel fractional flow reserve (vFFR) calculation

    vFFR is calculated from routinely taken angiography images during PCI using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands)

06

What researchers measure

Primary outcomes

  1. Rate of MACE defined as all-cause death, target-vessel myocardial infarction (TVMI) and target vessel revascularization (TVR).

    Time frame: 24 months

Secondary outcomes

  1. Rate of MACE defined as all-cause death, target-vessel myocardial infarction (TVMI) and target vessel revascularization (TVR).

    Time frame: 6 months, 12 months

  2. Rate of all-cause death

    Time frame: 6 months, 12 months, 24 months

  3. Rate of target-vessel myocardial infarction (TVMI)

    Time frame: 6 months, 12 months, 24 months

  4. Rate of target-vessel target vessel revascularization (TVR)

    Time frame: 6 months, 12 months, 24 months

  5. Symptoms of angina and quality of life assessed by the score of EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L)

    The EQ-5D-5L scale asses the patient's self-rated health in five categories (each category 1-5) - higher values indicate worse performance. Additionally, the patient fulfill vertical visual analog scale from 0 to 100, where higher scores indicate better function.

    Time frame: 6 months, 12 months, 24 months

  6. Symptoms of angina and quality of life assessed by score of the Seattle Angina Questionnaire (SAQ)

    The SAQ provides results for 6 categories. The patient can receive between 0 and 100 points in each category, where 100 represents the best score.

    Time frame: 6 months, 12 months, 24 months

  7. Correlation of post-percutaneous coronary intervention (PCI) vessel fractional flow reserve (vFFR) with score of Seattle Angina Questionnaire (SAQ).

    The SAQ provides results for 6 categories. The patient can receive between 0 and 100 points in each category, where 100 represents the best score. vFFR values are within the range 0-1, where higher values indicate better function.

    Time frame: 6 months, 12 months, 24 months

  8. Correlation of ΔvFFR with score of Seattle Angina Questionnaire (SAQ).

    The SAQ provides results for 6 categories. The patient can receive between 0 and 100 points in each category, where 100 represents the best score.

    Time frame: 6 months, 12 months, 24 months

  9. Correlation of post-percutaneous coronary intervention (PCI) vessel fractional flow reserve (vFFR) with score of EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L).

    The EQ-5D-5L scale asses the patient's self-rated health in five categories (each category 1-5) - higher values indicate worse performance. Additionally, the patient fulfill vertical visual analog scale from 0 to 100, where higher scores indicate better function. vFFR values are within the range 0-1, where higher values indicate better function.

    Time frame: 6 months, 12 months, 24 months

  10. Correlation of ΔvFFR with score of EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L).

    The EQ-5D-5L scale asses the patient's self-rated health in five categories (each category 1-5) - higher values indicate worse performance. Additionally, the patient fulfill vertical visual analog scale from 0 to 100, where higher scores indicate better function.

    Time frame: 6 months, 12 months, 24 months

  11. AUC for the optimal cutoff point for post-percutaneous coronary intervention (PCI) vessel fractional flow reserve (vFFR) for significant prediction of MACE

    MACE defined as all-cause death, target-vessel myocardial infarction (TVMI) and target vessel revascularization (TVR).

    Time frame: 6 months, 12 months, 24 months

  12. AUC for the optimal cutoff point for ΔvFFR useful for prediction of MACE

    MACE defined as all-cause death, target-vessel myocardial infarction (TVMI) and target vessel revascularization (TVR).

    Time frame: 6 months, 12 months, 24 months

  13. AUC for the optimal cutoff point for post-percutaneous coronary intervention (PCI) vessel fractional flow reserve (vFFR) useful for prediction of higher than median SAQ score.

    The SAQ provides results for 6 categories. The patient can receive between 0 and 100 points in each category, where 100 represents the best score. vFFR values are within the range 0-1, where higher values indicate better function.

    Time frame: 6 months, 12 months, 24 months

  14. AUC for the optimal cutoff point for post-percutaneous coronary intervention (PCI) vessel fractional flow reserve (vFFR) useful for prediction of higher than median EQ-5D-5L score.

    The scale asses the patient's self-rated health in five categories (each category 1-5) - higher values indicate worse performance. Additionally, the patient fulfill vertical visual analog scale from 0 to 100, where higher scores indicate better function. vFFR values are within the range 0-1, where higher values indicate better function.

    Time frame: 6 months, 12 months, 24 months

  15. AUC for the optimal cutoff point for ΔvFFR useful for prediction of higher than median SAQ score.

    The SAQ provides results for 6 categories. The patient can receive between 0 and 100 points in each category, where 100 represents the best score.

    Time frame: 6 months, 12 months, 24 months

  16. AUC for the optimal cutoff point for ΔvFFR useful for prediction of higher than median EQ-5D-5L score.

    The scale asses the patient's self-rated health in five categories (each category 1-5) - higher values indicate worse performance. Additionally, the patient fulfill vertical visual analog scale from 0 to 100, where higher scores indicate better function.

    Time frame: 6 months, 12 months, 24 months

  17. Rate of revascularization of any vessel due to exacerbation of angina symptoms.

    Decisions on the performance of revascularization will be made by the attending physician according to the clinical features and available methods.

    Time frame: 6 months, 12 months, 24 months

  18. Rate of definite and probable stent thrombosis.

    Time frame: 6 months, 12 months, 24 months

  19. Rate of clinically driven invasive coronary angiography due to exacerbation of angina symptoms.

    Decisions on the performance of invasive coronary angiography will be made by the attending physician according to the clinical features.

    Time frame: 6 months, 12 months, 24 months

  20. AUC for the value of in-stent vFFR gradient in predicting the rate of MACE

    vFFR values are within the range 0-1, where higher values indicate better function.

    Time frame: 6 months, 12 months, 24 months

  21. AUC for the value of 3-vessel post-PCI vFFR burden (sum of the vFFR estimated in the three main epicardial arteries) in predicting the rate of MACE

    3-vessel post-PCI vFFR will be defined as the sum of the post-PCI vFFR values derived for each vessel (left anterior descending, circumflex, right coronary artery).

    Time frame: 6 months, 12 months, 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jan 2027, 41 months after the start.

Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 41 months is above that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Feb 13, 2024
StartActual
Jul 3, 2023
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06255678
Responsible party
Mariusz Tomaniak (Tomaniak Mariusz MD PhD Assoc. Prof., Medical University of Warsaw) — Principal investigator
First posted
Feb 13, 2024
Start date
Jul 3, 2023
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Feb 13, 2024

Study contacts

Mariusz Tomaniak, MD PhD
Contact
mariusz.tomaniak@wum.edu.pl
+48 22 5991951
Karol Sadowski
Contact
karol.sadowski@wum.edu.pl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion